Search PubMed⌕ Search

Biomedical subjects

G Deppe

Publications and source records attributed to G Deppe.

At least 91 records · Page 5Linked to original sources
PubMed1984

Non-puerperal traumatic vulvar hematoma.

Two patients with non-puerperal traumatic vulvar hematoma due to physical assault are presented. Based on a review of the literature and our experience, a protocol for treatment is described with individualization of therapy emphasized.

Adult↗
PubMed1984

Use of indwelling right atrial catheter in gynecological oncology: a preliminary report.

Experience with the utilization of an indwelling right atrial catheter in patients with gynecological cancer is reviewed. The technique of placement is described and the complications in 21 patients are presented. Fever was the major complication in 5 out of 21 patients of whom 2 had positive blood cultures. The catheter had to be removed in 3 patients. The median duration of catheter placement was 45 days, the shortest being 8 hr and the longest being 1 year. Most of the patients were myelosuppressed or had no other venous sites accessible. A safe regimen for management of the catheter and indication for its removal are presented.

Catheters, Indwelling↗
PubMed1984

Limb salvage in recurrent vulvar carcinoma after rupture of femoral artery.

Bypass procedures in patients with gynecologic malignancies have been used rarely. Successful external iliac-femoral bypass to avoid amputation in a patient with a rupture of the femoral artery due to recurrent vulvar cancer is reported. It is suggested that vascular bypass procedures may be considered as alternatives to surgical amputation in the management of a few selected patients with recurrent vulvar cancer and vascular injury.

Blood Vessel Prosthesis↗
PubMed1984

Serum lactic dehydrogenase (SLDH) in germ cell malignancies of the ovary.

Serum lactic dehydrogenase may be elevated in patients with various neoplasms. In this report the authors describe four patients with ovarian germ cell malignancies who had elevated serum lactic dehydrogenase prior to treatment. There was a consistent correlation between these marker levels and the course of the disease. These preliminary data suggest that measurement of lactic dehydrogenase in sera of patients with ovarian germ cell malignancies may be helpful in assessing the effect of therapy.

Adolescent↗
PubMed1984

Multidrug treatment of advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study.

Patients (358) with advanced (FIGO stages III and IV) or recurrent endometrial cancer were treated with one of two regimens: 1) melphalan and 5-fluorouracil daily for four days, repeated every four weeks with megace daily for eight weeks and 2) adriamycin, 5-fluorouracil, and cyclophosphamide, intravenous bolus every 21 days with megace daily for eight weeks. All patients were randomized except for 63 with known cardiac disease who were assigned to regimen 1 (to avoid adriamycin) and studied separately. Stratification was effected for performance status, history of previous progestational therapy, presence or absence of measurable disease, and stage of disease. The objective response rate in those with measurable disease was 36.8% in both groups; 36.8% of each group had stable disease, and only 26.4% progressed on treatment. Response was unaffected by site of recurrence, time to first recurrence, presence or absence of previous treatment by progestational or radiation therapy, or age. Grade of tumor and performance status did affect response, although 44 of 57 objective responders had undifferentiated tumors. The two combinations achieved response rapidly, required careful supervision, and were especially useful in treating patients with usually poor prognostic features.

Adenocarcinoma↗
PubMed1983

Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation).

Between 1974 and 1982, 273 patients with epithelial cancer of the ovary (International Federation of Gynaecology and Obstetrics Stages III and IV) were randomized in four therapeutic trials. In Trial I Adriamycin plus cisplatin versus cisplatin alone versus thiotepa plus methotrexate was tested. The superiority of Adriamycin plus cisplatin in producing the best response rate led to its use as the reference arm in subsequent trials. All investigational arms included cisplatin plus other drugs (cyclophosphamide, Adriamycin, hexamethylmelamine, and thiotepa) in various combinations. Eligibility for second look required complete clinical remission and completion of at least 10 cycles of chemotherapy. To date, 73 second-look operations have been performed on randomized patients. An additional 43 nonrandomized patients underwent second-look procedures and are analyzed separately. Between 40% and 46% of patients treated with cisplatin regimens had no disease at second look. Cell differentiation and volume of postoperative disease did not influence response.

Aged↗
PubMed1983

Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancer.

Patients with advanced ovarian carcinoma, Stage III or IV (International Federation of Gynaecology and Obstetrics), were randomized to primary chemotherapy with doxorubicin (Adriamycin) and cisplatin plus or minus hexamethylmelamine, and cyclophosphamide (CHAP). The four-drug CHAP regimen produced a 57% complete clinical response rate and a 26% partial response rate for clinically evaluable patients. The median survival of CHAP patients is 25 months. The two-drug Adriamycin-cisplatin (AP) regimen produced a 43% complete response rate and a 35% partial response rate. The median survival is 18 months. The four-drug regimen produced a significantly longer median survival (28 versus 18 months) for patients with poorly differentiated tumors than for patients with well-differentiated tumors on either treatment. Examination of treatment failure or death by treatment, histology, and size of largest residual tumor and comparison to similar patients treated with AP in this and two preceding controlled trials also suggest that CHAP is superior to AP for patients with poorly differentiated tumors.

Altretamine↗
PubMed1983

Cerebral metastatic choriocarcinoma in the People's Republic of China.

Thirty-four patients with cerebral metastases from choriocarcinoma were treated between 1964 and 1978 by the Department of Gynecology of the Tumor Hospital Chung Shan Medical College, Kwongchow, People's Republic of China. Disease in 20.5% (7 of 34 patients) is currently in remission (12 to 120 months). Treatment was primarily by chemotherapy and Chinese herbs, with adjunctive craniotomy in selected patients. Myelosuppression was the main side effect.

Adult↗
PubMed1983

The rare indication for splenectomy as part of cytoreductive surgery in ovarian cancer.

Advanced ovarian carcinoma is being treated with aggressive debulking surgery including complete removal of the tumor whenever possible followed by adjuvant therapy. Secondary debulking including splenectomy in a patient with recurrent ovarian carcinoma is reported. It is suggested that splenectomy may have a place in the management of a few patients with ovarian cancer. The technique and complications of splenectomy are described.

Aged↗